Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Intravenous immune globulin: Adverse effects

INTRODUCTION AND OVERVIEW

Adverse reactions are reported in up to 20 percent of all intravenous immune globulin infusions [1]. The majority of adverse reactions are minor and transient; common examples include headache and mild rate-related reactions, such as chills or flushing. However, potentially serious systemic reactions of various types occur in 2 to 6 percent of patients [2]. These include thrombotic, renal, hematologic, and neurologic complications, as well as rare true anaphylactic reactions [3,4]. Many of these adverse effects are reduced by administering immune globulin subcutaneously, instead of intravenously.

Terminology — Immune globulin, intravenous (Human) will be referred to as "IVIG" in this review, because this term is commonly used by clinicians, although the abbreviation used by industry and various regulatory agencies is "IGIV."

Timing of reactions — Possible adverse effects may be divided by organ system (the approach used in this review) or by timing of onset, ie, immediate or delayed. Immediate reactions occur during the infusion, per se, and include rate-related reactions, true IgE-mediated anaphylaxis (in IgA-deficient patients), headache, and reactions related to concurrent infection. Delayed reactions generally occur hours to days after the infusion, and include headache/aseptic meningitis, acute kidney injury, hemolysis, venous thrombosis, and the possibility of myocardial infarction, transient ischemic attacks, and stroke. Some of these, particularly thrombotic events, may also occur during infusions, however.

The adverse effects attributed to IVIG will be reviewed here. General principles of immune globulin therapy, subcutaneous and intramuscular administration, and the use of IVIG in primary immunodeficiency, autoimmune, and hematologic disease are discussed separately. (See "General principles in the use of immune globulin" and "Subcutaneous and intramuscular immune globulin therapy" and "Immune globulin therapy in primary immunodeficiency" and "Intravenous immune globulin in hematologic disorders".)

RATE-RELATED REACTIONS

Rate-related reactions are relatively common and are rarely serious. In general, these reactions involve constellations of symptoms of two general types [5,6]:

                                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Sep 4, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17:241.
  2. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525.
  3. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27:171.
  4. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122:1238.
  5. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993; 9:254.
  6. Thampakkul S, Ballow M. Replacement intravenous immune serum globulin therapy in patients with antibody immune deficiency. Immunol Allergy Clin North Am 2001; 21:165.
  7. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986; 314:560.
  8. Björkander J, Hammarström L, Smith CI, et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987; 7:8.
  9. Vamvakas EC, Pineda AA. Allergic and anaphylactic reactions. In: Transfusion reactions, 2nd ed, Popovsky MA (Ed), American Association of Blood Banks Press, Bethesda, MD 2001. p.83.
  10. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012; 129:628.
  11. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child 2006; 91:651.
  12. Mathy I, Gille M, Van Raemdonck F, et al. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg 1998; 98:347.
  13. Scribner CL, Kapit RM, Phillips ET, Rickles NM. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994; 121:305.
  14. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121:259.
  15. Jarius S, Eichhorn P, Albert MH, et al. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. Blood 2007; 109:4376.
  16. Finkel AG, Howard JF Jr, Mann JD. Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications. Headache 1998; 38:317.
  17. Jolles S, Sewell WA, Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf 2000; 22:215.
  18. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60:1822.
  19. Zaidan R, Al Moallem M, Wani BA, et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 2003; 10:367.
  20. Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000; 59:77.
  21. Grillo JA, Gorson KC, Ropper AH, et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 2001; 57:1699.
  22. Mizrahi M, Adar T, Orenbuch-Harroch E, Elitzur Y. Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion. Case Rep Med 2009; 2009:861370.
  23. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000; 75:83.
  24. Katz KA, Hivnor CM, Geist DE, et al. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003; 139:991.
  25. Rajabally YA, Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci 2011; 308:124.
  26. Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013; 105:54.
  27. Caress JB, Hobson-Webb L, Passmore LV, et al. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009; 256:339.
  28. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339:662.
  29. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44:223.
  30. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 2003; 60:1736.
  31. Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci 2003; 24 Suppl 4:S222.
  32. Etscheid M, Breitner-Ruddock S, Gross S, et al. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang 2012; 102:40.
  33. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm355986.htm (Accessed on June 17, 2013).
  34. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29:173.
  35. Fakhouri F. [Intravenous immunoglobulins and acute renal failure: mechanism and prevention]. Rev Med Interne 2007; 28 Spec No. 1:4.
  36. Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999; 48:518.
  37. FDA drug warning 1998.
  38. Zhang R, Szerlip HM. Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy. South Med J 2000; 93:901.
  39. Cantú TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25:228.
  40. Ahsan N, Palmer BF, Wheeler D, et al. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994; 154:1985.
  41. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008; 51:491.
  42. Welles CC, Tambra S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010; 55:148.
  43. Nguyen MK, Rastogi A, Kurtz I. True hyponatremia secondary to intravenous immunoglobulin. Clin Exp Nephrol 2006; 10:124.
  44. Palevsky PM, Rendulic D, Diven WF. Maltose-induced hyponatremia. Ann Intern Med 1993; 118:526.
  45. Hollander RC. Recognizing maltose-induced hyponatremia. Ann Intern Med 1994; 120:248.
  46. Daphnis E, Stylianou K, Alexandrakis M, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007; 106:c143.
  47. Lawn N, Wijdicks EF, Burritt MF. Intravenous immune globulin and pseudohyponatremia. N Engl J Med 1998; 339:632.
  48. Bern M. Clinically significant pseudohyponatremia. Am J Hematol 2006; 81:558.
  49. Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003; 73:97.
  50. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2:193.
  51. Nakamura S, Yoshida T, Ohtake S, Matsuda T. Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta Haematol 1986; 76:115.
  52. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion 1986; 26:410.
  53. Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987; 82:633.
  54. Comenzo RL, Malachowski ME, Meissner HC, et al. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992; 120:926.
  55. Mohamed M, Bates G, Eastley B. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy. Br J Haematol 2013; 160:570.
  56. Pintova S, Bhardwaj AS, Aledort LM. IVIG--a hemolytic culprit. N Engl J Med 2012; 367:974.
  57. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48:1598.
  58. Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4:1993.
  59. Singh A, Arif F, Smith SD. Intravenous immunoglobulin-induced reversible neutropenia in a renal transplant patient. Clin Nephrol 2005; 64:246.
  60. Gerebenau MD. Transient neutropenia induced by intravenous immune globulin (letter). N Engl J Med 1992; 326:271.
  61. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992; 326:270.
  62. Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. J Pediatr Hematol Oncol 2005; 27:145.
  63. Lassiter HA, Bibb KW, Bertolone SJ, et al. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol 1993; 15:120.
  64. von Gunten S, Schaub A, Vogel M, et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006; 108:4255.
  65. Popovsky MA. Transfusion and lung injury. Transfus Clin Biol 2001; 8:272.
  66. Matsuda M, Hosoda W, Sekijima Y, et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharmacol 2003; 26:306.
  67. Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol 2012; 66:312.
  68. Centers for Disease Control and Prevention (CDC). Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994; 43:505.
  69. Bjøro K, Frøland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331:1607.
  70. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994; 331:1649.
  71. Goodman C, Chan S, Collins P, et al. Ensuring blood safety and availability in the US: technological advances, costs, and challenges to payment--final report. Transfusion 2003; 43:3S.
  72. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000; 14:94.
  73. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985; 25:516.
  74. Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43:1023.
  75. Biesert L. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 1996; 14 Suppl 15:S47.
  76. Lee DC, Stenland CJ, Hartwell RC, et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000; 84:77.